15 results on '"G. Batist"'
Search Results
2. Technology & tools development
- Author
-
E. Pefani, N. Panoskaltsis, A. Mantalaris, M. C. Georgiadis, E. N. Pistikopoulos, A. Aguilar-Mahecha, J. Lafleur, C. Seguin, M. Rosenbloom, E. Przybytkowski, M. Pelmus, Z. Diaz, G. Batist, M. Basik, J. Tavernier, L. Brunet, J. Bazot, M. Chemelle, C. Dalban, S. Guiu, C. di Martino, J. Lehtio, M. Branca, H. Johansson, M. Orre, V. Granholm, J. Forshed, M. Perez-Bercoff, L. Kall, K. V. Nielsen, L. Andresen, S. Muller, S. Matthiesen, A. Schonau, R. Oktriani, A. Wahyono, S. Haryono, A. Utomo, T. Aryandono, T. Gagnon-Kugler, C. Rousseau, T. Alcindor, R. Aloyz, S. Assouline, D. Bachvarov, L. Belanger, E. Camlioglu, M. Cartillone, B. Chabot, R. Christodoulopoulos, C. Courtemanche, A. Constantin, N. Benlimame, I. Dao, R. Dalfen, L. Gosselin, F. Habbab, M. Hains, T. Haliotis, T. H. Nielsen, M. Joncas, P. Kavan, R. Klink, A. Langlaben, M. Lebel, B. Lesperance, K. Mann, J. Masson, P. Metrakos, S. McNamara, W. H. Miller, M. Orain, L. Panasci, E. Paquet, M. Phillie, S. Qureshi, D. Rodrigue, A. Salman, A. Spatz, B. Tetu, A. Tosikyan, M. Tsatoumas, T. Vuong, R. Ruijtenbeek, R. Houtman, R. de Wijn, P. Boender, R. Hilhorst, Y. Cohen, A. Onn, A. Lax, A. Yosepovich, S. Litz, S. Kalish, R. Felemovicius, G. Hout-Silony, M. Gutman, M. Shabtai, D. Rosin, A. Valeanu, E. Winkler, M. Sklair-Levy, B. Kaufman, I. Barshack, V. Canu, A. Sacconi, F. Biagioni, F. Mori, A. di Benedetto, L. Lorenzon, S. di Agostino, A. Cambria, S. Germoni, G. Grasso, R. Blandino, V. Panebianco, V. Ziparo, O. Federici, P. Muti, S. Strano, F. Carboni, M. Mottolese, M. G. Diodoro, E. Pescarmona, A. Garofalo, G. Blandino, T. Ho, L. Feng, S. Lintula, K. A. Orpana, J. Stenman, S. El Messaoudi, F. Mouliere, M. del Rio, A. S. Guedj, C. Gongora, F. M. Molina, P. J. Lamy, E. Lopez-Crapez, F. Rolet, M. Mathonnet, M. Ychou, D. Pezet, A. R. Thierry, M. Manuarii, O. Tredan, T. Bachelot, G. Clapisson, A. Courtier, G. Parmentier, T. Rabeony, A. Grives, S. Perez, J. F. Mouret, D. Perol, S. Chabaud, I. Ray-Coquard, I. Labidi-Galy, P. Heudel, J. Y. Pierga, C. Caux, J. Y. Blay, N. Pasqual, and C. Menetrier-Caux
- Subjects
Engineering management ,Development (topology) ,Oncology ,business.industry ,Medicine ,Hematology ,business - Published
- 2012
- Full Text
- View/download PDF
3. The Peter Brojde Lung Cancer Centre: A Model of Integrative Practice
- Author
-
M. Grossman, G. Batist, and Jason Agulnik
- Subjects
medicine.medical_specialty ,Integrative Oncology ,Scope (project management) ,Management science ,business.industry ,target patterns ,media_common.quotation_subject ,Alternative medicine ,Psychological intervention ,Context (language use) ,Scientific evidence ,lung cancer ,integrative model of practice ,Complementary and alternative medicine ,nursing ,medicine ,Conceptual model ,integrative oncology ,Traditional Chinese Medicine ,whole-systems research ,Identification (biology) ,business ,media_common - Abstract
Background: The generally poor prognosis and poor quality of life for lung cancer patients have highlighted the need for a conceptual model of integrative practice. Although the philosophy of integrative oncology is well described, conceptual models that could guide the implementation and scientific evaluation of integrative practice are lacking. Purpose: The present paper describes a conceptual model of integrative practice in which the philosophical underpinnings derive mainly from integrative oncology, with important contributions from Traditional Chinese Medicine (tcm) and the discipline of nursing. The conceptual model is described in terms of its purpose, values, concepts, dynamic components, scientific evidence, clinical approach, and theoretical underpinnings. The model argues that these components delineate the initial scope and orientation of integrative practice. They serve as the needed context for evaluating and interpreting the effectiveness of clinical interventions in enhancing patient outcomes in lung cancer at various phases of the illness. Furthermore, the development of relevant and effective integrative clinical interventions requires new research methods based on whole-systems research. An initial focus would be the identification of interrelationship patterns among variables that influence clinical interventions and their targeted patient outcomes.
- Published
- 2012
- Full Text
- View/download PDF
4. Oral and Poster Papers Submitted for Presentation at the 5th Congress of the EUGMS 'Geriatric Medicine in a Time of Generational Shift September 3–6, 2008 Copenhagen, Denmark
- Author
-
M. T. Lonergan, B. Hovmand, M. Sánchez Cuervo, M. Tange Kristensen, C. Yau, Stefano Volpato, K. Christensen, K. Guha, J. Duggan, Y. Sawayama, J. F. M. de Jonghe, R. Rosenberg, K. Goupal, N. R. Jørgensen, P. Jordá, H. Kubšová, B. Riou, M. Monami, L. Özdemir, B. R. Duus, J. M. Fernandez Ibanez, Add Neuromed Study, S. Maertens, R. Winder, N. Akdemir, Carmelinda Ruggiero, F. Cambien, D. Bonnet, G. Barban, M. Fuentes, C. Datu, B. Ni Mhaille, D. G. Seymour, Toshio Hayashi, S. Lord, I. Kjeken, E. J. Schaefer, I. Raducanu, E. Tung, A. Truyols Bonet, D. Power, N. Morel, S. Edwards, C. Vigder, K. Promsopa, C. Geny, L. Derame, A. Dukat, A. Vilches-Moraga, K. Lihavainen, Z. Yang, R. M. Pircalabu, P. Huber, C. Eddy, A. Cella, C. Napoli, A. B. L. Pedersen, A. Fedeli, I. Sleiman, P. Weber, W. Kitisomprayoonkul, E. L. Marcus, K. Given, J. Sinclair-Cohen, S. O. Mahony, S. Vinkler, M. Krogseth, S. Otaguro, C. V. U. Øresund, D. Schoevaerdts, R. Pircalabu, B. Brack, H. Sasaki, F. Retornaz, I. Ionescu, M. Dubiel, J. Florian, L. Rokkedal, N. Quinlan, G. Dell’aquila, B. Way, C. Ionescu, T. Bermejo Vicedo, P. Eikelenboom, D. O’neill, T. Koga, A. Kachhia, M. R. Padilla Clemente, G. Batist, K. Moynier Vantieghem, P. Moerland, J. M. Bjordal, A. Pilotto, M. Michelet, R. Shafiei, Mirko Petrovic, J. Sulicka, J. Wagle, T. B. Wyller, J. Hrubanová, B. Stensrød, R. Ferretti, E. Turcu, S. Opris, A. Moreira, A. Zamora Mur, F J Martín Sánchez, N. Cogan, Marcello Maggio, Y. Kreslov, D. Ni Chroinin, G. Hanson, L. Kaiser, P. A. Kocaturk, S. Trainor, P. Takahashi, D. R. Collins, L. Campos, A. Björg Jönsdóttir, M. Cappuccio, V. Massart, T. Pattison, G. Notaridis, S. L. Ktvelä, S. Ghiorghe, Ruth Piers, L. Viati, M. Hollmann, Anja Velghe, Mikko P. Björkman, A. Zwinderman, K. Damkjær, P. Marsden, G. Cuneo, N. Bartoli, P. Gómez De Abia, A. Vilches Moraga, P. Campbell, Didem Sener Dede, B. Kirby, J. Oristrell, C. O’regan, T. Sander Pedersen, A. Hickey, R. Rozzini, B. Jansen, G. Fisher, N. Vogt-Ferrier, E. Kovari, B. Gasperini, K. Kalisvaart, N. Rye Jørgensen, K. Soda, U. Muster, K. Overgaard, J. Duiez-Domingo, M. Urbano, A. Oto, M. C. Cavallini, R. J. Van Marum, F. Gozukara, M. Cabrera Orozco, M. T. Olcoz-Chiva, A. Colvez, M. Di Bari, I. Cilesi, M. Migale, W. He, C. Dwyer, S. Engels, F. Hermmann, D. Small, Adam L. Gordon, Roberto Bernabei, R. Hnidei, C. Gonzalez-Rios, L. B. Husted, B. Dallapiccola, A. Moreau, R. Baron, U. Sveen, D. Chaiwanichsiri, A. Lopez Sierra, D. Villaneau, A. Mathur, G. Vedel Sørensen, P. Hemmi, F. Lattanzio, T. Frühwald, C. Marquis, A. Forest, B. Dalla Piccola, S. Lee, E. Ogawa, F. Coindreau, C. Rada, F. Lally, M. Yamada, K. Bakker, F. Comte, L. C. P. G. M. De Groot, H. L. Jørgensen, A. T. Isk, P. Schwarz, E. Portegijs, M. Kawakami, P. Giannakopoulos, A. Escolante Melich, M. O’ Connor, M. Rafanelli, P. Abete, M. Trabucchi, G. Clpaera, J. Vierendeels, M. Ramos, A. Salpakoski, G. Ziere, M. Ai, T. Fujisawa, K. I. Sørensen, C. Berard, K. Cobbaert, R. Fellin, M. Angel Mas, Phyo K. Myint, Burcu Balam Yavuz, K. Benmedjahed, P. Lampela, S. White, L. del Bianco, E. O. Ospedali Galliera, A. Frøland, L. Kozlov, M. T. Pacitti, P. Dave, B. Oeser, K. Kanaya, M. Rachita, Jean-Pierre Michel, Nadia Sourial, D. O’ Mahony, A. A. Piette, H. O’brien, K. Eiklid, A. J. Cruz-Jentoft, C. Shou, T. Bruun Wyller, J. Geerts, J. Korevaar, A. H. Johansen, P. Nimann Kannegaard, T. Korfitsen, A. Ayub, P. Baker, C. Scarcelli, A. Juszczak, L. S. Seest, A. Blundell, S. Bandinelli, P. A. F. Jansen, A. Maraviglia, E. S. Cankurtaran, B. Orhan, J. Vanakoski, K. J. Kalisvaart, M. Sakai, J. Oh, M. Henry, I. Kiviranta, S. Sanders, T. Mariani, A. H. Ranhoff, Mehmet Cankurtaran, B. Böhmdorfer, A. Tekeira, A. Lund, A. M. J. Maclullich, J. Hayashi, M. J. Lopez-Sanchez, S. M. I. Park, S. Willicombe, B. L. Langdahl, E. Lupeanu, A. Michael, R. Dias, G. Berrut, E. Ruffolo, D. Giet, Marianne Schroll, G. Onose, S. D. Shenkin, J. Driesen, T. Katsuya, C. Moe, M. San-Martin, Koenraad Vandewoude, A. Bambi, E. Shelley, C. Lamanna, B. Mc Eniry, B. Yoo, C. Colombi, H. Ekstrom, P. Gallagher, O. Mkhailova, A. Hnidei, F. P. Cariello, I. Moy, J. M. Vega Andion, G. Balci, F. Orso, W. Schrauwen, Patrizia Mecocci, J. L. Gallais, J. Saunders, M. Koefoed, J. Petrovicova, E. Paredes-Galan, C. Gutiérrez Fernández, Simon Lovestone, N. Berg, N. Weerasuriya, S. Biswas, K. Van Puyvelde, C. Chamot, T. Rantanenv, C. Rosen, K. O’connor, J. Ryg, L. Le Saint, D. A. Jones, M. Boncinelli, S. Baldasseroni, P. Barbisoni, E. Jones, C. F. Ambien, N. Dzerovych, P. Barry, A. Falanga, M. T. Olcoz Chiva, A. Skerris, S. Samandel, Antonio Cherubini, N. Binkley, A. Landi, P. Belli, G. Ditloto, M. Mellingsaeter, K. Wieczorowska-Tobis, L. Alonso Boix, C. Fernandez, V. Strelkova, G. Carmona, S. Amici, S. Mehrabian, J. Lietava, M. Iso-Aho, M. Masotti, I. G. Ftta, J. Carbonero Malberti, I. Carriere, A. Toornvliet, N. Grygoryeva, J. Soubeyrand, M. Cavalieri, Z. Malla, K. D. Pedersen, G. Clapera, J. M. Anton, N. R. Chopra, P. Eiken, S. Kapucu, G. Ventura, E. Cirinei, O. Vazquez, M. Checa, M. Filipa Seabra Pereira, R. Sylvest Mortensen, A. Osawa, J. Cunniffe, M. White, V. Batalha, A. Chatterjee, K. Bjøro, D. Zintchouk, E. Guillemard, R. Vreeswijk, C. Quinn, B. Romboli, G. Pepe, F. Simonsen, B. Morosanu, S. S. Celik, E. Kaykov, C. Bouras, B. Schousboe, N. van der Velde, P. Mowinckel, L. Toutous Trellu, J. Frimann, N. Vergis, T. Wulff, M. Salonoja, H. Doruk, A. Gonzalez, Dominique Benoit, L. Santos, Y. Ben-Israel, B. Grandal Leiros, F. Addante, C. Twomey, C. Sieber, C. Bonomini, P. Ziccardi, D. Carratelli, T. Jørgensen, F. Kasagi, A. Cebrian, M. Frisher, M. S. Brandt, W. Hussain, J. Mora, M. Alen, Maurits Vandewoude, C. Lidy, M. Burke, M. Mørch, A. Lyager, F. Huwez, J González Del Castillo, M. Cankuran, C. Prete, S. Anniss, S. Briggs, E. Bozoglu, S. Sipila, C. Fernandez Rios, H. Nomura, N. Faucher, L. Al-Dhahi, M. Gross, M. G. Longo, C. Schiaffini, H. Petersen, S. Crane, K. Brixen, C. Yucel, A. Leiro Manso, B. Yavuz, J. Petermans, W. Nielsen, T. Jokinen, C. L. Tofteng, D. Wan-Chow-Wah, B. Fantino, I. Barat, M. J. Lopez Sanchez, A. E. Larsen, E. Farrelly, S. Rostoft Kristjansson, J. M. Vega-Andion, V. Andrei, E. Pressel, B. Ni Bhuachalla, Steven Boonen, D. Simoni, M. G. Matera, E. Santillo, R. Sival, Dirk Vogelaers, Anna Skalska, S. Van Der Mark, H. Hirai, V. M. Chisciotti, R. Scoyni, M. Kallinen, A. Lopez-Sierra, E. Paredes Galan, D. Hagedorn, J. B. Lauritzen, Sölve Elmståhl, P. Mikes, M. Cohen, T. Vahlberg, L. E. Matzen, Gerda Verschraegen, H. Blain, E. Rees, R. Melton, T. L. J. Tammela, D. Aw, R. Miralles, E. Lopilato, M. van Zutphen, S. Ghorghe, N. Nissen, M. Lopponen, A. Oestergaard, A. Sorva, F. O’sullivan, M. Vanmeerbeek, A. Sclater, V. Juliebo, M.E. Fuentes Ferrer, S. Prada, E. Bryden, I. Maeve Rea, N. Furusyo, K. Cho, H. Cronin, F. Tigoulet, V. Povoroznyuk, F. Paris, P. Clarkson, P. E. Cotter, S. Rodriguez-Justo, F. Mazzella, E. de Waele, S. Trasciatti, O. Beauchet, E. Mannucci, K. N. Raun, C. Verdejo, S. Pautex, M. M. Mørch, P. Giniès, R. Garavan, J. Nobrega, S. Kinsella, L. Skippari, Howard Bergman, J. E. B. Jensen, T. Lee, P. Godart, B. Montero Errasquin, C. Nyhuus, Reijo S. Tilvis, G. Mancioli, D. Dawe, M. D’imperio, I. Miralles, J. Serra, M. Baglioni, C. Fallon, Y. Tatsukawa, J. Forristall, J. C. Leners, G. D’onofrio, J. de Backer, K. Flekkøy, L. Kyne, V. Dubois-Ferrière, C. Ryan, M. P. Sibret, A. Nesbakken, V. Ochiana, T. Iwamoto, E. Lotti, M. Marchionni, A. Clemmensen, J. Puustinen, S. Amor Andres, L. Wileman, Anette Hylen Ranhoff, S. Gillett, F. Lauretani, M. Gullo, H. Meluzínová, M. Seidahamd, P. de Antonio, A. Sgadari, E. Jespersen, A. Morelli, Palacios Huertas, C. Fraguglia, A. S. Rigaud, H. E. Andersen, B. Wizner, D. Fedak, J. Boddaert, Shaun T. O'Keeffe, D. O. ’Neill, B. Felli, C. Morales Ballesteros, S. Mcintosh, P. Such, O. Akyol, I. S. Young, J. M. Guralnik, A. Leiro-Manso, L. P. D’ambrosio, S. Rooij, G. Gold, H. Lee, C. Sohrt, A. Egan, D. Susanne Nielsen, C. Gravina, P. Rinaldi, C. Lestrup, S. F. Syed Farooq, M. Nuotio, L. Rexach Cano, C. Maraldi, F. Mangiaasche, Z. Mikes, E. M. Damsgaard, C. Di Serio, S. Pecchioni, S. Caplan, E. Gonzalez, M. Baccini, Y. Caine, J. Gladman, J. M. Ribera, B. Lundgren, V. Sharma, M. Morocutti, Sara Ercolani, B. H. C. Stricker, C. Popescu, M. Carpena-Ruiz, M. Verny, B. Hofman, A. Ungar, Y. Kumei, E. Topikova, L. Franceschi, S. Hussain, V. Serafini, K. Shipman, F. Sioulis, T. Coughlan, S. Bhat, B. Comert, K. Engedal, B. Kream, A. Iguchi, D. F. Vitale, M. Fornal, K. Kristiansen, I. Palma-Reis, E. Sixt, C. H. Foss, R. Rizzoli, M. Bartley, B. Fure, P. Freitas, C. Fernández Alonso, R. Njemini, F. Kelleher, A. Zamora Catevilla, S. Hoeck, F. Rashidi, J.M. Ribera Casado, M. Honing, A. Rajska-Neumann, B. D. Pedersen, A. Martins, C. M. J. Van Der Linden, D. Sharpe, R. Grue, Denis O'Mahony, J. Van der Heyden, J. Cristoffersen, Marianna Noale, U. Sommeregger, V. Goffredo, A. Qvist, Y. Akkuþ, M. T. E. Puts, M. Luque, M. P. De Antonio García, T. Takagi, N. Carroll, A. Salakowski, M. Belladonna, A. Hylen Ranhoff, S. Otokozawa, C. Ekdahl, E. Delgado Silveira, Stijn Blot, H. Mcgee, U. Senin, G. C. Parisi, S. Pedersen, F. Rengo, A. Renom, E. Vestbo, Y. Akkus, G. Van Hal, S. Murphy, V. Ducasse, G. Ryzhak, M. I. Arranz Peña, W. Knol, V. Lesauskaite, F. Patacchini, S. Abe, M. Narro-Vidal, C. Lund, N. Hayashi, M. van Breemen, H. Ohnishi, M. Torrente-Carballido, B. Bogen, H. Kayihan, Z. Tuna, C. Verdejo-Bravo, B. Battacharya, F. M. Borgbjerg, Kudret Aytemir, A. C. Drenth-Van Maanen, F. Gori, O. Duems, T.J.M. van der Cammen, Servet Ariogul, P. Villarroel, M. Kat, N. Petitpierre, I. Akyar, M. Franceschi, M. Ohishi, S. Cassano, Roy L. Soiza, T. Patel, A. M. Herghelegiu, M. Clarfield, S. Ballentyne, L. Lambertucci, Cm. Pena, A. Bayer, A. Salam, E. Moriarty, C. Roux, Y. Takasugi, M. García, C. Rodriguez-Pascual, P. Mikus, Y. Akyar, M. Torrente Carballido, V. Vayda, F. Rønholt, M. Khayat, K. Ina, O. Hazer, M. Falconer, H. N. Jacobsen, R. Custureri, H. Kasem, T. Bandholm, A. Allue Bergua, M. Levi, R. Rehman, M. Monette, C. Verdejo Bravo, O. Millot, N. Caffrey, Y. Kano, C. Cherubini, J. Kolesar, S. Maeshima, J. Fox, P. Aarnio, E. Henderson, J. Monette, M. MacMahon, L. Rytter, J. Nurminen, A. Abbas, A. S. Whitehead, G. Longobardi, Zekeriya Ulger, M. Hamada, A. Sofia Duque, Luigi Ferrucci, P. Lavikainen, J. Kennedy, I. Saez, E. Hegarty, Stefania Maggi, J. Touchon, A. Chandra, A. Bhangu, M. Labib, A. Rnould, A. Bojan, S. Mukherjee, N. Ferrara, F. Raschilas, G. Popescu, C. Annweiler, D. Hevey, D. Seripa, C. Danneels, I. Crome, M. Karlsson, Y. Kamiya, C. Carvell, I. Trani, T. van der Ploeg, G. Zulian, J. Bencke, V. Curran, P. Gherasim, B. Sejtved, R. Meade, Rose Anne Kenny, V. Curiale, A. Yu-Ballard, E. Azevedo, A. Leiros, P. Gil Gregorio, J. Gonzalez Armengol, H. Rakugi, M. C. Esculier, O. Poire, R. Raz, R. Gugliotta, M. Carpena Ruiz, Tony Mets, Ivan Bautmans, T. Karasevskaya, P. Eoin Cotter, T. Masud, C. Jeandel, K. Leckie, J. P. Lopes, R. Isoaho, A. E. Evans, F. Lacoin, C. Cho, B. Vincent, M. Lazaro, R. Cecchetti, M. Carpena, A. Kavanagh, S. Juhl Pedersen, Niccolò Marchionni, C. Swine, François Herrmann, G. O. Kavas, F. J. Garcia Garcia, S. Quintela, G. I. Prada, C. Hertogh, S. Sun Kapucu, P. Granberg, S. Byrne, R. Mcdermott, R. Van Der Stichele, A. M. Mello, A. Waldir Bezerra, J. de Jonghe, L. F. Moreno Ramiez, A. de Tena Fontaneda, M. H. Saldanha, H. Kehlet, G. V. Sørensen, M. Jylhä, J. Silvestre, K. Czabanowska, L. Gowran, F. Albertí Homar, M. de Saint-Hubert, R. Huupponen, P. le Lous, T. Bertsch, P. Dieppe, R. Topor-Madry, R. Van Gara, W. Bemelmans, V. Polcarová, C. Donnellan, B. Jørgensen, G. Leandro, S. L. Kivela, C. Boubakri, Sirpa Hartikainen, K. Ferguson, Z. Barrou, E. Costanzi, H. Hilleret, L. Danbaek, A. O’hanlon, C. Hürny, O. G. Olaru, V. Seux, C. Divoy, M. Mowe, E. Holm, H. J. Heppner, J. Martin, M. Isik, B. Gryglewska, A. Lilja, E. Romero, I. Pillay, V. Kijowska, M. Therese Lonergan, A. Alfaro Acha, M. Uyanik, A. Gabelle, P. Bueso, S. Sinha, M. Corritore, T. Shingo, E. Lacey, L. Cascavilla, R. Sulkava, K. Terumalai, S. Pellerito, Gaetano Crepaldi, R. Moe-Nilssen, Francesco Cacciatore, J. Breda, J. M. Del Rey, J. Teixeira, N. B. Nielsen, E. Granot, D. Speijer, S. A. Anstey, G. Masotti, I. G. Fita, S. Krajèík, P. Brynningsen, S. Maeda, N. Vanden Noortgate, J. Wiersinga, M. Teixeira Veríssimo, J. Cooke, N. Van Den Noortgate, K. Daly, M. M. Bisschop, A. Galmés Truyols, W.A. van Gool, J. Fernandez Soria, C. Sánchez Castellano, A. M. Cervera, E. Mossello, T. Lindhardt, C. Boulanger, E. Oziol, C. Hendriksen, A. M. Pazienza, L. Farner, P. Bastiani, F. Horgan, A. Deniz, P. Ammann, H. Takeoka, J. Lauritsen, L. Sandvik, S. S. Kapucu, I. Nakagawa, A. Jung, L. Brewer, Anne-Marie Schott, S. Zanieri, A. Teixeira, G. Parisi, P. Lund Nielsen, J. Holckova, P. Alcalde, B. Whelan, K. Toyoda, B. Dieudonne, G. Guerra, Meltem Halil, E. Garcia-Villar, R. Paz Maya, C. E. Mogensen, M. O’connor, A. Bonnerup Vind, L. Vich Martorell, F. Tarantini, Katarzyna Szczerbińska, I. Ozerov, R. Turk, M. Kamigaki, E. Mirewska, H. Bayes, S. Arino, P. Lyngholm-Kxærby, B.C. van Munster, F. Konishi, A. Morrione, C. Pena, P. Harbig, D. Gradinaru, F. Kee, B. Knold, L. Aiello, T. de Man, Renaat Peleman, Taina Rantanen, P. Birschel, P. Crome, R. Meyling, V. Khavinson, D. H. Kim, T. Luukkaala, Q. Garcia, K. Elkholy, D. Gillain, M. L. Seux, S. Greffard, P. Kjear, S. Sihvonen, Patricia M. Kearney, Tomasz Grodzicki, F. Favier, Dominique Vandijck, E. Palummeri, F. Caldi, Y. Parel, E. Jorge, L. O’connor, S. Dahlin Ivanoff, L. Tiret, K. Adie, G. Lucchetti, M. Lauridsen, A. C. Berggren, M. Simon, D. Adane, P. O. Lang, and V. Niro
- Subjects
Gerontology ,Geriatrics ,0303 health sciences ,medicine.medical_specialty ,Nutrition and Dietetics ,030309 nutrition & dietetics ,Geriatrics gerontology ,business.industry ,media_common.quotation_subject ,Alternative medicine ,Medicine (miscellaneous) ,03 medical and health sciences ,Presentation ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,Geriatrics and Gerontology ,business ,Quality of Life Research ,media_common - Published
- 2008
- Full Text
- View/download PDF
5. Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer
- Author
-
G. Batist
- Subjects
Oncology ,medicine.medical_specialty ,Cardiotoxicity ,Anthracycline ,business.industry ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Metastatic breast cancer ,Breast cancer ,Therapeutic index ,Quality of life ,Internal medicine ,Medicine ,Surgery ,Doxorubicin ,business ,Adjuvant ,medicine.drug - Abstract
Summary Improving the therapeutic index of anthracycline-based regimens in the management of metastatic breast cancer is a goal that physicians strive for in orderto improve quality of life and increase the small fraction of long-term disease-free survivors that have been observed in studies using anthracycline-based regimens. There are supporters and opponents of continuous and dose-intensive therapy for improving quality of life and providing a survival advantage, but the risk of cumulative toxicity associated with anthracycline-based regimens, especially, doxorubicin, is limiting in these approaches. Myocet™, has equivalent antitumour efficacy to doxorubicin, but significantly less cardiotoxicity. Consequently, the recommended cumulative lifetime dose of Myocet is 780 mg/m 2 , compared with 450 mg/m 2 for doxorubicin. By using Myocet in the metastatic setting, and perhaps eventually in the adjuvant treatment for primary breast cancer, an increased number of cycles can be givenwithin the cardiotoxicity risk threshold, improving quality of life by delaying relapse. This improvement in therapeutic index may contribute to the fraction of long-term disease-free survivors and fulfils a previously unmet need in the overall management of breast cancer.
- Published
- 2001
- Full Text
- View/download PDF
6. [Untitled]
- Author
-
C. L. Granvil, Murray P. Ducharme, M. Di Marco, Irving W. Wainer, and G. Batist
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Metabolite ,Population ,Pharmaceutical Science ,Pharmacology ,chemistry.chemical_compound ,Pharmacokinetics ,Internal medicine ,medicine ,Pharmacology (medical) ,education ,Chemotherapy ,education.field_of_study ,Ifosfamide ,business.industry ,Organic Chemistry ,Cancer ,Metabolism ,medicine.disease ,Nitrogen mustard ,Endocrinology ,chemistry ,Molecular Medicine ,business ,Biotechnology ,medicine.drug - Abstract
Purpose. To describe the pharmacokinetics of R- andS-Ifosfamide (IFF), and their respective 2 and 3 N-dechloroethylated (DCE)metabolites (R2-, R3-, S2, S3-DCE-IFF) in cancer patients.
- Published
- 2000
- Full Text
- View/download PDF
7. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group
- Author
-
A. Jorgensen, C. Cripps, R. Mayer Steinacker, Y. Merrouche, A. Man, G. Batist, J. Schuller, M. Wirth, S. Pyrhonen, G. Vantrappen, H. Bergermann, B. Weinerman, A. Jakobsen, A. Scaletzky, J. Seitz, Jean A. Maroun, H. Ravn, J. Bury, E. Francois, D. Lutz, R. Johansson, H. Smith, C. Blaes, F. Porzsolt, B. May, E. Pannuti, M. Budde, John A. Levi, Peter Sherman, J. Skillings, R. Goel, J. Heise, M. Froimtchuk, P. Guillou, M. De Lourdes Lopes De Oliveira, W. Kocha, P. Lankisch, P. Selby, K. Bertelsen, M Namer, John Stewart, Euan Walpole, R. Mertelsmann, J. Primrose, S. Holmstrom, P. Carey, J. Mejlholm, David R. Bell, Damien Thomson, U. Ward, G. Boos, Allan Solomon Zimet, V. Fosser, R. Luykx, T. Shore, G. Massimini, Stephen P. Ackland, Michael D. Green, E. Lindegaard Madsen, J. Salomon, M. Colleoni, A. K. L. Yap, John Zalcberg, G. Cartei, M. Schupp, E. E. Holdener, M. Giovannini, R. Egeli, C. Berg, P. Rebattu, Y. Becouarn, N. Brunsgaard, L. Cockey, C. Sodomann, L. Lepoutre, M. Reginster, M. Kjaer, E. Sandberg, J. Greving, L. De Facq, S. Somers, R. Brunet, O. P. Isokangas, E. Van Cutsem, C. Gadeberg, U. Fogl, E. Bajetta, P. Rougier, V. Kataja, and D. Dalley
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Leucovorin ,Interferon alfa-2a ,Interferon alpha-2 ,Drug Administration Schedule ,law.invention ,Advanced colorectal cancer ,Randomized controlled trial ,Interferon ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Remission Induction ,Interferon-alpha ,Middle Aged ,Combined Modality Therapy ,Recombinant Proteins ,Survival Rate ,Fluorouracil ,Toxicity ,Female ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
PURPOSE To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the combination of 5-FU with leucovorin (LV) in the treatment of advanced colorectal cancer. PATIENTS AND METHODS A total of 496 previously untreated colorectal cancer patients were randomized to receive either Roferon-A (9 MIU) subcutaneously three times per week, with 5-FU (750 mg/m2/d) by continuous intravenous (i.v.) infusion (CIV) on days 1 to 5, then, after a 9-day hiatus, as a weekly i.v. bolus at the same dose (IFN/5-FU); or LV (200 mg/m2/d) by i.v. infusion plus 5-FU (370 mg/m2/d) by i.v. bolus on days 1 to 5, repeated every 4 weeks (LV/5-FU). RESULTS There were no significant differences between IFN/5-FU and LV/5-FU in the overall response rate (21% v 18%), duration of response (7.3 v 6.2 months), or survival time (median, 11.0 v 11.3 months). Toxicity profiles differed; constitutional symptoms and myelosuppression were more frequent and more severe with IFN/5-FU, and gastrointestinal symptoms with LV/5-FU. More patients interrupted treatment for adverse events (AEs) with IFN/5-FU than with LV/5-FU. Five treatment-related deaths occurred with each regimen. CONCLUSION The combination IFN/5-FU produced response rates, response durations, and survival times similar to those with LV/5-FU. Biochemical modulation of 5-FU by either IFN or LV appears to result in equivalent efficacy; however, fewer patients were able to tolerate the specified IFN/5-FU combination used in this study.
- Published
- 1995
- Full Text
- View/download PDF
8. ChemInform Abstract: Design and Synthesis of Analogues of Vitamine E: Antiproliferative Activity Against Human Breast Adenocarcinoma Cells
- Author
-
Huiping Qin, Graham W. Burton, G. Batist, S. X.‐L. You, Prabhat Arya, N. Alibhai, and Moulay A. Alaoui-Jamali
- Subjects
Vitamine e ,Chemistry ,Cancer research ,medicine ,Adenocarcinoma ,General Medicine ,medicine.disease ,Human breast - Published
- 2010
- Full Text
- View/download PDF
9. Drug resistance in cultured rat liver epithelial cells spontaneously and chemically transformed
- Author
-
A. Woo, G. Batist, and Ming-Sound Tsao
- Subjects
Methylnitronitrosoguanidine ,Cancer Research ,Drug Resistance ,Gene Expression ,Drug resistance ,Biology ,medicine.disease_cause ,Epithelium ,chemistry.chemical_compound ,In vivo ,Gene expression ,medicine ,Animals ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Cells, Cultured ,Glutathione Transferase ,chemistry.chemical_classification ,Membrane Glycoproteins ,Glutathione peroxidase ,Epithelial Cells ,gamma-Glutamyltransferase ,General Medicine ,Glutathione ,Blotting, Northern ,Molecular biology ,In vitro ,Rats ,Multiple drug resistance ,Cell Transformation, Neoplastic ,Liver ,chemistry ,Biochemistry ,Doxorubicin ,RNA ,Carcinogenesis - Abstract
Cultured rat liver epithelial cells (RLE) transformed with repeated treatments of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) demonstrate many features of the common biochemical phenotype of multidrug resistance (MDR) seen in vivo in 'resistant hepatocytes'. The cells have increased glutathione-S-transferase placental subunit (GST-Yp), gamma-glutamyltranspeptidase (GGT), glutathione (GSH) and glutathione peroxidase and are resistant to MNNG. Phenotypically identical RLE cells spontaneously transformed by selective culture conditions showed low levels of GGT and GST and were not resistant to MNNG. Both chemical and spontaneous transformants are cross resistant to doxorubicin although resistance is consistently greater in chemical transformants. No direct correlation was found between the degree of resistance to doxorubicin and MDR gene expression in either of the chemically or spontaneously transformed RLE cells. These observations suggest that in chemical carcinogenesis, other mechanisms of drug detoxification are involved and that MDR expression is not a consistent feature.
- Published
- 1992
- Full Text
- View/download PDF
10. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate
- Author
-
S Damian, Daniela Vasilescu, Elias Georges, Bertrand J. Jean-Claude, G Batist, Lawrence Panasci, A. Mustafa, Brian Leyland-Jones, Z. Damian, and Zhi Liu
- Subjects
medicine.medical_treatment ,Breast Neoplasms ,Pharmacology ,Biochemistry ,chemistry.chemical_compound ,Breast cancer ,medicine ,Tumor Cells, Cultured ,Humans ,Doxorubicin ,skin and connective tissue diseases ,Cytotoxicity ,IC50 ,Chemotherapy ,business.industry ,Megestrol Acetate ,medicine.disease ,Tamoxifen ,chemistry ,Drug Resistance, Neoplasm ,Megestrol ,Megestrol acetate ,Female ,business ,medicine.drug - Abstract
Acquired drug resistance is a major factor in the failure of doxorubicin-based chemotherapy in breast cancer. We determined the ability of megestrol acetate and/or tamoxifen to reverse doxorubicin drug resistance in a doxorubicin-resistant breast cancer line (the human MCF-7/ADR). The cytotoxicity of doxorubicin, megestrol acetate, and/or tamoxifen was determined in the sensitive and resistant cell lines utilizing the sulphorhodamine B assay. Tamoxifen alone produced an IC50 (concentration resulting in 50% inhibition of control growth) of 10.6 microM, whereas megestrol acetate alone resulted in an IC50 of 48.7 microM in the MCF-7/ADR cell line. The IC50 of doxorubicin in MCF-7/ADR was 1.9 microM. Neither megestrol acetate alone nor tamoxifen alone at 1 or 5 microM altered the IC50 of doxorubicin. However, the combination of tamoxifen (1 or 5 microM) and megestrol acetate (1 or 5 microM) synergistically sensitized MCF-7/ADR cells. Additionally, megestrol acetate and tamoxifen inhibited iodoarylazidoprazosin binding to P-glycoprotein, and, in their presence, there was an increased doxorubicin accumulation in the MCF-7/ADR cells. Furthermore, the combination of tamoxifen and megestrol acetate had much less effect on the cytotoxicity of doxorubicin in MCF-7 wild-type cells. Clinically achievable concentrations of tamoxifen and megestrol acetate can largely sensitize MCF-7/ADR to doxorubicin. The combination of these three drugs in a clinical trial may be informative.
- Published
- 1996
11. Pharmacokinetics of Pamidronate Disodium in Cancer Patients after a Single Intravenous Infusion of 30-, 60- or 90-mg Dose over 4 or 24 Hours
- Author
-
V. John, S. Schoenfeld, R. Knight, G. Batist, Keith K. H. Chan, J. Seaman, W. K. Cheung, L. Brunner, and A. Brox
- Subjects
Pharmacology ,Drug ,Disposition kinetics ,business.industry ,media_common.quotation_subject ,Cancer ,Drug administration ,General Medicine ,Urine ,medicine.disease ,High-performance liquid chromatography ,Linear relationship ,Pharmacokinetics ,medicine ,Pharmacology (medical) ,business ,media_common - Abstract
The objective of this study was to determine the pharmacokinetics of pamidronate disodium in plasma and urine after a single intravenous infusion of the drug to cancer patients at risk for developing bone metastases. Thirty-six patients were randomized into six treatment groups to receive 30-, 60- or 90-mg doses of the drug by 4- or 24-h intravenous infusions. Plasma and urine samples were collected at intervals for up to 144 h after drug administration and were assayed for pamidronate disodium using validated reversed-phase HPLC methods. The percentage of the administered dose excreted in urine following a 4- or 24-h infusion of 30-, 60- or 90-mg pamidronate disodium ranged from 30% to 60% except for one individual who excreted 96% by this route of elimination. There was a linear relationship between amount of drug excreted in urine and dose. Curve fitting of ARE (amount of drug to be excreted in urine) data indicated that the disposition kinetics of the drug was consistent with a biexponential process with overall mean plus minus S.D. half-life values of 2.1 plus minus 1.8 and 26.9 plus minus 8.7 h for the alpha and beta phases, respectively. The results of this study showed that the drug exhibited dose proportionality in its pharmacokinetic behavior over the 30--90-mg range regardless of whether it was infused over a 4- or 24-h interval.
- Published
- 1994
12. Effect of proliferative state on glutathione S-transferase isoenzyme expression in cultured rat liver epithelial cells
- Author
-
G. Batist, Annie Woo, and Ming-Sound Tsao
- Subjects
Cancer Research ,Biology ,Isozyme ,Cell Line ,Gene expression ,medicine ,Animals ,RNA, Messenger ,Glutathione Transferase ,Confluency ,Dactinomycin ,Cell growth ,Liver Neoplasms ,Nucleic Acid Hybridization ,General Medicine ,RNA Probes ,Blotting, Northern ,Molecular biology ,In vitro ,Rats, Inbred F344 ,Rats ,Gene Expression Regulation, Neoplastic ,Isoenzymes ,Glutathione S-transferase ,Biochemistry ,Liver ,Cell culture ,biology.protein ,Cell Division ,medicine.drug - Abstract
A specific biochemical phenotype is expressed during chemical hepatocarcinogenesis, which includes increased activity of the various isoenzyme forms of glutathione S-transferase (GST) composed of class alpha (Ya/Yc), class mu (Yb) and class pi (Yp) gene products. In vitro cell lines of normal and chemically transformed rat liver epithelial cells provide an opportunity to examine the regulation of expression of GST isoenzymes. We have studied the effect of the state of proliferation in culture on both the enzymic activity and the isoenzyme-specific mRNA expression. In normal rat liver epithelial cells (WB-F344), basal expression of the Yp subunit decreases, and of the Yb subunit increases, in cells at confluence compared with those in logarithmic-phase growth. In a subline of WB-F344 cells that has been chemically treated in vitro (GN6), there was greater Yp expression; however, the effect of growth status on both subunits was the same as in the nontransformed WB-344 cells, and the Ya subunit was not expressed. Inhibition of RNA synthesis with actinomycin D was limited, demonstrating pronged half-lives of the GST mRNAs, and shows a slightly greater decrease in GST-Yp specific mRNA levels in the confluent cells. Also nuclear run-off experiments demonstrate identical transcription rate in confluent and pre-confluent cells. These data suggest that the increase in Yp steady-state RNA in preconfluent cells is due to increased stability of the GST-Yp mRNA. In tumor cells derived from GN6 cells, the regulatory effects of growth status on the Yb and Yp expressions were absent. However, in these cells Ya subunit was expressed and this was subject to the effects of cell proliferation. We conclude that the growth status of cells in culture exerts a significant regulatory control on the GST isoenzyme gene expression. The effects are probably mediated at independent regulatory sites in each gene. The state of transformation of rat liver epithelial cells may determine responsiveness to this effect.
- Published
- 1991
13. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines
- Author
-
Annie Woo, Robyn L. Schecter, Dierdre Greene, Shirley Lehnert, and G. Batist
- Subjects
medicine.medical_specialty ,Drug Resistance ,Breast Neoplasms ,Biology ,Biochemistry ,chemistry.chemical_compound ,Internal medicine ,Methionine Sulfoximine ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Buthionine sulfoximine ,Cytotoxicity ,Buthionine Sulfoximine ,Glutathione Transferase ,Pharmacology ,Mammary Neoplasms, Experimental ,Metabolism ,Glutathione ,Molecular biology ,In vitro ,Rats, Inbred F344 ,Rats ,Endocrinology ,chemistry ,Verapamil ,Cell culture ,Doxorubicin ,Female ,Efflux ,medicine.drug - Abstract
The effects of GSH depletion in a human breast cancer cell line and a multi-drug resistant subline (ADRr) were determined in a number of experimental conditions. The ADRr cells contained lower GSH concentration which cannot be explained solely on the basis of differences in cell kinetics, and yet the rate-limiting synthetic enzyme gamma-glutamylcysteine synthetase was increased 2-fold. Inhibition of GSH synthesis by BSO resulted in more rapid and more pronounced GSH depletion in ADRr compared to the wild-type cells, suggesting that enhanced GSH utilization and efflux in the resistant cells account for the lowered basal concentration. In addition, the gamma-glutamyl moiety salvage enzyme gamma-glutamyltranspeptidase was reduced markedly in the ADRr cell line. Since these cells have overexpression of the efflux pump protein P-glycoprotein, we examined the effects on cellular GSH of inhibition of the pump's function by verapamil. We found that verapamil significantly depleted cellular GSH. In a rat mammary carcinoma cell line selected in Adriamycin for multi-drug resistance, a similar molecular phenotype has been described including diminished cellular GSH concentration. Verapamil treatment of these cells also resulted in significant depletion of cellular GSH. These results are consistent with the recent report that combined treatment of BSO and verapamil has an additive effect on cytotoxicity. It is likely that decreased basal GSH concentration is due to oxidation and conjugation of it in reactions catalyzed by the enhanced peroxidase and GST found in these cells.
- Published
- 1991
14. A phase I/II study of vaccination with autologous dendritic cells (DCs) transfected with autologous amplified tumor-derived mRNA in patients with stage IV renal cell carcinoma (RCC)
- Author
-
Jennifer J. Knox, D. Ornstein, Charles A. Nicolette, F. Miesowicz, M. K. K. Wong, G. Batist, J. Corcos, L. H. Finke, Kimryn Rathmell, and Michael A.S. Jewett
- Subjects
Cancer Research ,Messenger RNA ,business.industry ,chemical and pharmacologic phenomena ,Transfection ,Tumor-Derived ,medicine.disease ,Vaccination ,Oncology ,Immunity ,Renal cell carcinoma ,Immunology ,Medicine ,Antigen-presenting cell ,business ,CD8 - Abstract
4710 Background: DCs are antigen presenting cells stimulating cell-mediated immunity by effects on both CD4+ and CD8+ T-cells. We report results of a phase I/II study of a vaccine comprised of matu...
- Published
- 2005
- Full Text
- View/download PDF
15. The use of glycine as nitrogen source by Escherichia coli K12
- Author
-
S Isenberg, G Batist, P Weyman, E B Newman, V Kapoor, and J. Fraser
- Subjects
L-Serine Dehydratase ,Time Factors ,Nitrogen ,Auxotrophy ,Glycine ,Biophysics ,Biology ,medicine.disease_cause ,Cleavage (embryo) ,Biochemistry ,Serine ,Escherichia coli ,medicine ,Doubling time ,Amino Acids ,Molecular Biology ,Nitrogen cycle ,Glycine Hydroxymethyltransferase ,chemistry.chemical_classification ,Glycine cleavage system ,Enzyme ,chemistry ,Cell Division - Abstract
The use of glycine as nitrogen source by Escherichia coli K12 involves L-serine as obligatory intermediate. The pathway includes glycine cleavage enzymes, serine transhydroxymethylase and probably L-serine deaminase. This conversion of glycine to serine occurs in prototrophic strains only when glycine is used as nitrogen source. The growth rate with glycine as sole nitrogen source is slow; apparent doubling time 360 min.
- Published
- 1976
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.